Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α

Eyad Elkord*, Deborah J. Burt, Anette Sundstedt, Örjan Nordle, Gunnar Hedlund, Robert E. Hawkins

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology